Differences

This shows you the differences between two versions of the page.

--- pharmaceutical_companies:ophirex [2022/04/16 05:46]
liam
+++ pharmaceutical_companies:ophirex [2024/11/11 18:28] (current)
liam [External links]
@@ Line 7: / Line 7: @@
 ===== Affiliates =====
+[[Derrick Rossi]], co-founder of [[pharmaceutical_companies:Moderna]], is an advisor to Ophirex.((Farooqui, S. (2021, July 6). //Moderna co-founder using mRNA technology to treat venomous snakebites.// Global News. https://archive.ph/URhV7))
+==== Funding ====
+Ophirex is funded by multiple awards from the [[:US Department of Defense]], a grant from [[:Wellcome Trust]], and the [[:World Health Organization]].((Rao, S. (2020, March 2). //Ophirex receives Wellcome Trust award to advance clinical development of novel snakebite treatment.// Business Wire. https://archive.ph/LHsYv)) ((Karon, P. (2020). //Snakebites are a deadly threat worldwide. Who’s behind the push for a new treatment?// Inside Philanthropy. https://web.archive.org/web/20220413132035/https://static1.squarespace.com/static/5eb10eb62bf19e1bbec031bc/t/60c38b9ca1a11d3f55c2fb7d/1623427997415/Inside+Philanthropy+2020-12-17+Snakebites.pdf)) ((//Broad Spectrum Envenomation Treatment.// SBIR. Retrieved April 16, 2022, from https://archive.ph/T9toA))
 ==== Staff ====
 ^ Name  ^ Position  ^
-| Nancy Koch  | Chief Executive Officer  |
+| Nancy Koch  | Chief Executive Officer((//Ophirex - Overview, News & Competitors.// ZoomInfo. Retrieved April 15, 2022, from https://web.archive.org/web/20220416034702/https://www.zoominfo.com/c/ophirex-inc/398629525))  |
 | Rebecca Carter  | Vice President, Program Operations  |
 | Kathleen Dotson  | Vice President, Finance  |
+| Dana Miletic  | Operations Contracts Administrator  |
+| Jack Tupman  | Executive  |
+| [[Sunita Rao]]  | Senior Executive Administrator((//Sunita Rao.// LinkedIn. Retrieved April 15, 2022, from https://www.linkedin.com/in/sunitarao/))  |
-===== Antivenom =====
+===== Products =====
-In August 2017, Ophirex licensed varespladib from [[pharmaceutical_companies:Eli Lilly]] and [[pharmaceutical_companies:Shionogi]].((Lewin, M. (2017, August 28). //Ophirex Licenses Lilly - Shionogi Data for Novel Snakebite Treatment Development Program.// Bloomberg. https://archive.ph/5pvD3))
+==== Antivenom ====
-==== BRAVO Study ====
+In August 2017, Ophirex licensed [[pharmaceutical_companies:varespladib]] from [[pharmaceutical_companies:Eli Lilly]] and [[pharmaceutical_companies:Shionogi]].((Lewin, M. (2017, August 28). //Ophirex Licenses Lilly - Shionogi Data for Novel Snakebite Treatment Development Program.// Bloomberg. https://archive.ph/5pvD3))
+=== COVID-19 ===
+{{:pharmaceutical_companies:ophirex_stairs_trial_spot.png?150 |}}
+In 2020, Ophirex evaluated varespladib for treatment of [[:Acute Respiratory Distress Syndrome]] (ARDS), a common cause of death in [[:COVID-19]] patients. Despite the apparent winding down of the pandemic, their STAIRS trial continues.((Ophirex, Inc., & Premier Research International LLC. (2022, March 22). //A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2.// ClinicalTrials.gov. https://archive.ph/jo7R9))
+=== BRAVO Study ===
 {{:pharmaceutical_companies:ophirex_bravo_trial_spot.jpeg?150 |}}
-Ophirex is running a clinical trial titled "Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO)" in collaboration with [[Premier Research International]].((Ophirex, Inc., & Premier Research International LLC. (2022, February 9). //Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes.// ClinicalTrials.gov. https://archive.ph/xNuHy))
+Ophirex is running a clinical trial titled "Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO)" in collaboration with [[:Premier Research International]].((Ophirex, Inc., & Premier Research International LLC. (2022, February 9). //Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes.// ClinicalTrials.gov. https://archive.ph/xNuHy))
+===== External links =====
+  * [[https://wiki.whiteroseintelligence.com/en/Ophirex|White Rose Wiki]]